Turning Point Brands (TPB) Is Down 14.7% After Possible FDA Delays On Oral Nicotine Approvals

Simply Wall St.04-03 19:27

In late March 2026, reports suggested the FDA may delay authorization of certain oral nicotine products, including those Turning Point Brands has pending, as agency scientists weigh risks to new users...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2624985657?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/5131000-choice2-main-header/1585186906815","is_english":true,"pubTime":"2026-04-03 19:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2624985657","market":"hk","top_or_hot":-1,"title":"Turning Point Brands (TPB) Is Down 14.7% After Possible FDA Delays On Oral Nicotine Approvals","media":"Simply Wall St.","content":"<div>\n<p>In late March 2026, reports suggested the FDA may delay authorization of certain oral nicotine products, including those Turning Point Brands has pending, as agency scientists weigh risks to new users...</p>\n\n<a href=\"https://simplywall.st/stocks/us/food-beverage-tobacco/nyse-tpb/turning-point-brands/news/turning-point-brands-tpb-is-down-147-after-possible-fda-dela\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Turning Point Brands (TPB) Is Down 14.7% After Possible FDA Delays On Oral Nicotine Approvals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTurning Point Brands (TPB) Is Down 14.7% After Possible FDA Delays On Oral Nicotine Approvals\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-03 19:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/food-beverage-tobacco/nyse-tpb/turning-point-brands/news/turning-point-brands-tpb-is-down-147-after-possible-fda-dela><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In late March 2026, reports suggested the FDA may delay authorization of certain oral nicotine products, including those Turning Point Brands has pending, as agency scientists weigh risks to new users...</p>\n\n<a href=\"https://simplywall.st/stocks/us/food-beverage-tobacco/nyse-tpb/turning-point-brands/news/turning-point-brands-tpb-is-down-147-after-possible-fda-dela\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LABU","symbol_name":"三倍做多标普生物-Direxion","start_time":0,"source_url":"https://simplywall.st/stocks/us/food-beverage-tobacco/nyse-tpb/turning-point-brands/news/turning-point-brands-tpb-is-down-147-after-possible-fda-dela","article_id":"2624985657","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/5131000-choice2-main-header/1585186906815"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/food-beverage-tobacco/nyse-tpb/turning-point-brands/news/turning-point-brands-tpb-is-down-147-after-possible-fda-dela","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2624985657","pubTimestamp":1775215666,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In late March 2026, reports suggested the FDA may delay authorization of certain oral nicotine products, including those Turning Point Brands has pending, as agency scientists weigh risks to new users and children.\nThis hesitancy introduces fresh regulatory uncertainty around modern oral pouches, a category that has become central to Turning Point Brands’ growth plans.\nNext, we’ll examine how the potential for longer FDA approval timelines could reshape Turning Point Brands’ previously...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LABU":"三倍做多标普生物-Direxion","BK4588":"碎股","BK4585":"ETF&股票定投概念","TPB":"Turning Point Brands Inc.","BK4075":"烟草"},"translate_title":"FDA可能推迟口服尼古丁审批后，Turning Point Brands(TPB)股价下跌14.7%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TPB":1.5,"LABU":1.5},"content_text":"In late March 2026, reports suggested the FDA may delay authorization of certain oral nicotine products, including those Turning Point Brands has pending, as agency scientists weigh risks to new users and children. This hesitancy introduces fresh regulatory uncertainty around modern oral pouches, a category that has become central to Turning Point Brands’ growth plans. Next, we’ll examine how the potential for longer FDA approval timelines could reshape Turning Point Brands’ previously optimistic investment narrative. Outshine the giants: these 22 early-stage AI stocks could fund your retirement.AdvertisementTurning Point Brands Investment Narrative RecapTo own Turning Point Brands today, you have to believe its pivot toward modern oral nicotine pouches can offset pressure in legacy tobacco and justify ongoing investment in sales, marketing, and distribution. The FDA’s hesitancy around oral nicotine authorizations directly affects the company’s most important short term catalyst, because slower approvals could delay new product launches in a category that already carries the biggest regulatory risk in the story. The most relevant recent update is management’s 2026 revenue guidance for Modern Oral gross sales of US$220 million to US$240 million, with net revenue of US$180 million to US$190 million. That outlook was set before the latest FDA reports, so investors now need to weigh whether any extended review timelines could affect how quickly Turning Point can scale those pouch sales and validate the bullish expectations around its modern oral platform. Yet behind the growth story, investors should be aware that any shift in how regulators treat flavored modern oral products could... Read the full narrative on Turning Point Brands (it's free!)Turning Point Brands’ narrative projects $890.0 million revenue and $163.0 million earnings by 2029. This requires 24.3% yearly revenue growth and about a $104.8 million earnings increase from $58.2 million today.Uncover how Turning Point Brands' forecasts yield a $132.50 fair value, a 84% upside to its current price.Exploring Other PerspectivesTPB 1-Year Stock Price Chart Four fair value estimates from the Simply Wall St Community span roughly US$105 to US$159 per share, underscoring how far opinions can stretch. Readers should weigh those views against the heightened regulatory uncertainty now facing modern oral pouches and consider how different approval timelines might influence Turning Point Brands’ ability to sustain its recent momentum.Explore 4 other fair value estimates on Turning Point Brands - why the stock might be worth just $105.20!Form Your Own VerdictDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your Turning Point Brands research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.Our free Turning Point Brands research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Turning Point Brands' overall financial health at a glance.Searching For A Fresh Perspective?Our top stock finds are flying under the radar-for now. Get in early:Find 62 companies with promising cash flow potential yet trading below their fair value.The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.Rare earth metals are the new gold rush. Find out which 26 stocks are leading the charge.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Turning Point Brands might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2624985657","isCrawlerRequest":true}